Biocon Limited is an Indian biopharmaceutical company, Biocon was founded in Bangalore in 1978 by Kiran Mazumdar-Shaw. The company manufactures generic Active Pharmaceutical Ingredients (APIs) which are exported to more than 120 countries including USA and Europe.
It also manufactures biosimilar insulin and antibodies, which are sold as branded formulations across India. Biocon’s biosimilar products are sold in the markets in both bulk and formulation forms.
If we look at its products in the Indian market, its formulations include Metabolics, Oncology, Immunotherapy and Nephrology products. Some of the leading brands of Biocon in India include Insugen (RH-insulin), Basalog (glargine), Biomab EGFR (nimotuzumab), Blisto (glimepiride + metformin), Canmab (trastuzumab), Evertor (everolimus), Tacrograf (tacrolimus), Alzumab Are.
Syngene International Limited (Syngene) is a subsidiary of Biocon, which is engaged in the field of contract research services. Both Biocon and Syngene companies employ more than 10,000 workers.
Simultaneously, Biocon also established Biocon Biopharmaceuticals Pvt. Ltd. Which entered into a joint venture with the Cuban institute CIMAB in 2003 to develop a series of mAbs and cancer vaccines as well as market them.
Following which in 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company. same year
In January 2008, NeoBiocon FZ LLC also incorporated a research and marketing pharmaceutical company based in Abu Dhabi. Also incorporated Biofusion Therapeutics Limited in the year 2021 during Kovid-19. It is 100% owned by Biocon.
Biocon Share price targets 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030,2040
We here at financesharetargets. in is going to give you approximate information about stock forecast, price prediction and target for 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030 and 2040 please keep one thing in mind that this forecast,
prediction or any The target is just a suggestion given by our analysis. The forecast/prediction which will be correct is almost impossible. Errors always exist in any analysis, but we try our best to give you good price stock predictions/predictions.
Biocon share price target 2023
If you look at the share price of Biocon on NSE, the company has given a return of about 6.36% from July to last month, while looking at the maximum returns of the company, the company has given a return of about 435.43%, which is very good.
For many years, the same company has given good returns to its shareholders, the same company is continuously moving towards growth and the way the company’s share price can be seen continuously increasing, it can be inferred that Biocon share price target For 2023, the first target can be achieved at ₹ 270 and the second target at ₹ 300.
Biocon Share Price Target 2024
Biocon is an Indian biopharmaceutical company with a strong focus on building capability in manufacturing quality APIs, strengthening its portfolio by achieving significant share in global and domestic markets, and is present in more than 120 countries including USA and Europe.
Delivering its products in the U.S. as well as selling its biosimilar products in many emerging markets in both bulk and formulation form is the specialty of the company, from which we can understand the good position of the company and considering which, according to our analysis, Biocon Share Price Target 2024 The first target for ₹ 320 and the second target can be at ₹ 360
Biocon Share Price Target 2025
The company is continuously growing by increasing its revenue, because talking about the market cap of the company, its market cap is around Rs 31,155 crore and the company is a mid cap company, the same company is continuously working to expand its market cap.
And according to the figures of 2023, the company’s net income has seen an increase of about ₹ 787 crore, after which the way the company’s revenue is seen increasing, it can be estimated that in the near future its more developed Along with being Biocon Share Price Target till 2025, the first target of ₹ 380, the second target can be at ₹ 420.
Biocon Share Price Target 2026
Biocon has customers globally in more than 120 countries including USA and Europe and continuously works to provide life saving treatments and relief to these customers and for this company has a large and well distributed network.
Through which the company succeeds in delivering its services to the right customers at the right time, thus the company is continuously moving towards good performance, which can be expected that in the coming times, Biocon Share Price Target for 2026 will become the first Target can be at ₹440 and another target at ₹480
Biocon Share Price Target 2027
A global biopharmaceutical company, Biocon offers a wide range of products across 36 brands across four therapeutic divisions of Diabetology, Nephrology, Oncology and Cardiology.The company aims at empowering everyone to have access to affordable and quality medicines.
In this way, the company keeps its special place for its products, so that looking at the good condition of the company, it can be estimated that the company can grow further in the same way, according to our analysis, Biocon Share Price Target 2027 The first target for ₹ 500 and the second target can be at ₹ 540
Biocon Share Price Target 2028
Company is an emerging company which is continuously moving ahead with the times through its development, for this the company is continuously working. Along with this, during the Kovid-19 pandemic in 2021, Biocon Biologics and Serum Institute of India have developed vaccines,
A joint agreement was also signed for commercialization of biologic drugs and antibody therapy. In this understanding, Biocon offered to sell 15% of its biologics subsidiary to Serum Institute of India, in exchange for 100 million annual doses of vaccines being supplied by Serum to Biocon for 15 years. In the same way, the company is constantly expanding its presence at the global level as well.
The company has a good global presence, along with which the company is continuously working to increase this presence, so that in the coming times, the company will have more opportunities. Biocon Share Price Target for 2028 can be expected to develop further and with which the profit of the company will increase. The first target for Biocon Share Price Target 2028 can be at ₹ 560 and the second target at ₹ 600.
Biocon Share Price Target 2029
The company is also ahead ethically and socially. Biocon has also not held back in investing heavily on development of new processes, spending on quality assurance protocols and continuous process improvement by supplying high quality at affordable cost.
This shows the specialty of the company which helps in increasing the confidence of the customers towards the company, so that the company’s stock will increase with the sale of the company’s products in the near future, with the expectation of better returns, according to our analysis Biocon Share Price Target 2029 The first target for ₹620 and the second target can be at ₹660.
Biocon Share Price Target 2030
The company is working to address unmet medical needs globally through a portfolio of differentiated and high quality lifesaving biotherapeutics. The company has harnessed innovative science to make affordable drug availability for some of the world’s most expensive drugs through its generics and biosimilars.
Simultaneously, the company is striving to provide generic versions of drugs such as statins and immunosuppressants to a larger number of patients by supplying its high-quality APIs. In this way, the company is continuously working for its development, so that with the development of the company, the first target for Biocon Share Price Target 2030 can be achieved at ₹ 680 and the second target at ₹ 750.
Biocon Share Price Target 2040
The way the company is developing its large production capacity and is striving to increase sales internationally, the company’s good growth prospects can be estimated in the coming times, given our analysis of Biocon Share Price The first target for Target 2040 can be ₹950 and the second target can be at rs.1100.
RISK OF BIOCON SHARE
BIOCON is a pharma industry company and it has many competing companies in the pharma industry and the way every business has ups and downs from time to time, we can see similar ups and downs in BIOCON too and this is It is possible that in the coming time the company may incur some losses.
FUTURE OF BIOCON
The company is working to provide high quality pharmaceutical products of international standards to the general markets from which expansion is expected in the times to come.
What is the target price of Biocon share in 2025?
Share Price Target till 2025, the first target of ₹ 380, the second target can be at ₹ 420.
Is Biocon a good buy for long term?
What analysts suggest. “Biocon stock has already made a meaningful bottom and here risk-reward is favourable in the long term.
What is the share price of Biocon in 2030?
Biocon Share Price Target 2030 can be achieved at ₹ 680 and the second target at ₹ 750.
Which share to buy for 2025?
Multi-Bagger Penny Stocks For 2025
|Name||Current Market Price||Annual Range|
|South Indian Bank||INR 14.00||INR 7.25 – INR 21.80|
|Yes Bank||14||INR 12.10 – INR 24.75|
|Trident Ltd||INR 26.20||INR 25.05 – INR 57.40|
|Bajaj Hindusthan Sugar||INR 12.90||INR 8.35 – INR 22.35|
What is the dividend of Biocon in 2023?
For the year ending March 2023 Biocon has declared an equity dividend of 30.00% amounting to Rs 1.5 per share